Achillion Pharmaceuticals, Inc., (Nasdaq:ACHN) a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it has entered into definitive agreements for the purchase of $50.1 million of Achillion's common stock and warrants in a private placement financing with a select group of institutional and accredited investors, namely Domain Associates, Clarus Ventures, Quaker BioVentures and Pappas Ventures. The investment in Achillion consists of the sale and issuance of 19,755,101 shares of common stock at a price of $2.49 per share, the consolidated closing bid price reported by NASDAQ on August 17, 2010, as well as the sale and issuance of warrants to purchase 0.35 shares of common stock for each share of common stock at a price of $0.125 per warrant share. The warrants, which represent the right to acquire an aggregate of 6,921,285 shares of common stock, have a seven-year term from the date of issuance and will be exercisable at a price of $3.1125 per share. The transaction is expected to close on or about August 20, 2010, subject to the satisfaction of certain customary closing conditions.
The Company expects net proceeds at closing of approximately $50.0 million after the deduction of offering expenses. Funding from the financing will be used to advance Achillion's pipeline of antiviral candidates for hepatitis C including ACH-1625, a protease inhibitor expected to enter phase 2 clinical trials next month, ACH-2684, a pan-genotypic protease inhibitor and ACH-2928, an NS5A inhibitor, the latter two preclinical candidates with investigational new drug applications planned for early 2011.
"We believe this financing gives us the resources to meaningfully advance our portfolio of clinical candidates for chronic HCV infection to significant milestones," said Michael Kishbauch, President and Chief Executive Officer of Achillion. "Our portfolio is led by protease inhibitor ACH-1625, a potentially best-in-class compound. ACH-1625 has already demonstrated clinical proof of concept as a potent inhibitor of HCV NS3 protease, with a remarkably clean safety and tolerability profile, a unique PK profile, and once-daily dosing. That compound is followed by pan-genotypic inhibitor ACH-2684 and NS5A inhibitor ACH-2928, both of which we anticipate will enter the clinic in early 2011. With several potential combinations, some of which could operate synergistically, we are quite excited about the possibility of initiating combination studies of ACH-1625 with our other inhibitors as soon as possible."
The securities sold in this private placement have not been registered under the Securities Act of 1933, as amended (the "Securities Act"), or applicable state securities laws, and accordingly may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act and such applicable state securities laws. The Company has agreed to file a registration statement with the Securities and Exchange Commission registering the resale of the shares of common stock issued in this private placement and the shares of common stock issuable upon the exercise of the warrants issued in the private placement.
This release does not constitute an offer to sell or the solicitation of an offer to buy the securities, nor shall there be any sale of the securities in any state in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of such state. Any offering of the securities under the resale registration statement will only be by means of a prospectus.
Urine RNA analysis shows promise for detecting genitourinary diseases